Rigel Pharmaceuticals RIGL Prepaid research and development costs

Other financials

Revenue$58.8M+10.3%

Gross profit$54.2M+10.8%

Operating income$11.9M-7.0%

Net income$8.7M-24.4%

EPS (diluted)$0.44-30.2%

Cash & equivalents$24.5M-46.6%

Total debt$68.4M+5,079%

Total equity$399.9M+2,054%

Total assets$504.6M+187%

Operating cash flow$2.7M+405%

CapEx$73.0K—

Free cash flow-$22.0M—

Market cap$684.39M+102%

Enterprise value$728.29M+148%

P/E1.9×-7.2×

P/S2.3×+0.6×

Gross margin93.4%+3.7pp

Operating margin41.6%+19.9pp

Net margin121.5%+103pp

FCF margin-61.7%—

Return on equity174.1%—

Debt / equity0.2×+0.1×

Current ratio2.6×+0.4×

Reported directly by Rigel Pharmaceuticals in its filing.

Tagged under the XBRL concept rigl:PrepaidResearchAndDevelopmentCosts.

The official record: Rigel Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and see it in context, right in your chat.

What is Rigel Pharmaceuticals's prepaid research and development costs?: Rigel Pharmaceuticals (RIGL) reported prepaid research and development costs of $5.2M in Q1 2026.